Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01200862 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men
A Phase 2 study, sponsored by Mereo BioPharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT01200862 is a Phase 2 study that was terminated before completion, run by Mereo BioPharma. The registered enrollment target is 29 participants.
The verdict
NCT01200862, a Phase 2 study, was terminated before completion, sponsored by Mereo BioPharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
This study is designed as a 2-part study, with Part 1 being open-label to best determine the appropriate dose levels to use in Part 2, which has a randomized, double-blind, placebo controlled design. The study aims to assess the safety and tolerability of BGS649, and determine whether or not BGS649 is able to normalize testosterone levels and improve insulin sensitivity in obese, hypogonadotropic hypogonadal (OHH) men
Interventions
- DRUG Placebo
- DRUG Investigational new drug company code: BGS649
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01200862
The ClinicalTrials.gov registry entry for NCT01200862 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mereo BioPharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01200862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01200862 about?
NCT01200862 is a clinical study titled "Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men". This study is designed as a 2-part study, with Part 1 being open-label to best determine the appropriate dose levels to use in Part 2, which has a randomized, double-blind, placebo controlled design. The study aims to assess the safety and tolerability of BGS649, and determine whether or not BGS649 ...
What is the current status of trial NCT01200862?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2010-08. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01200862?
The interventions under investigation include: Placebo (DRUG), Investigational new drug company code: BGS649 (DRUG).
Who is sponsoring clinical trial NCT01200862?
This trial is sponsored by Mereo BioPharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.